Clearmind Medicine Inc. — Form 6-K Summary
Reporting period: November 2023; filed November 21, 2023. Clearmind Medicine Inc. is a foreign private issuer filing under Form 20-F.
Business Context and Corporate Action
The filing incorporates a November 21, 2023 press release titled “Clearmind Medicine Announces 1-for-30 Reverse Share Split.” The filing text provided does not include the detailed terms, effective date, or trading information for the reverse split.
Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes Versus Prior Period
The reported material event is the announced 1-for-30 reverse share split. The filing text does not state the number of shares affected, the post-split share count, treatment of fractional shares, or any change to authorized shares or capital structure.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance, operational outlook, management commentary, risk disclosures, contingencies, or unusual items are provided in the filing text. The reverse share split may affect the company’s share price and share count, but its intended purpose and expected consequences are not clearly described in the supplied text.
Key Facts to Verify
- Effective date of the 1-for-30 reverse share split.
- Applicable exchange and commencement date for split-adjusted trading.
- Pre- and post-split shares outstanding and treatment of fractional shares.
- Whether authorized shares, outstanding securities, options, warrants, or convertible instruments are adjusted.
- The complete Exhibit 99.1 press release for the company’s stated rationale and additional terms.